The fact that the FDA is considering ending the trial early is a strong testament to the efficacy of BTM. Short term, this would likely provide a SP boost. Long term, it's an outstanding disruptive cost effective technology that will grow exponentially regardless of the trial completion date.
- Forums
- ASX - By Stock
- PNV
- PNV - Banter and General Comments
PNV
polynovo limited
Add to My Watchlist
1.06%
!
$1.16

PNV - Banter and General Comments, page-11643
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.16 |
Change
-0.013(1.06%) |
Mkt cap ! $804.8M |
Open | High | Low | Value | Volume |
$1.18 | $1.20 | $1.16 | $1.167M | 993.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
47 | 23601 | $1.16 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.17 | 50371 | 37 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
51 | 23299 | 1.160 |
17 | 45298 | 1.155 |
37 | 150680 | 1.150 |
21 | 98744 | 1.145 |
10 | 32508 | 1.140 |
Price($) | Vol. | No. |
---|---|---|
1.165 | 50405 | 36 |
1.170 | 46303 | 15 |
1.175 | 100696 | 11 |
1.180 | 38272 | 10 |
1.185 | 221715 | 6 |
Last trade - 13.59pm 26/06/2025 (20 minute delay) ? |
Featured News
PNV (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online